

Annual Report 2022-23

# Embracing the Unpredictable.

# Achieving the **Remarkable.**

# **OUR APPROACH TO REPORTING**

#### About this report

This Report is aligned with the International Integrated Reporting Council's (IIRC) globally accepted framework. Through this document, Metropolis Healthcare Limited ('Metropolis' or 'MHL' or 'Our Company') aims to strengthen its communication with the stakeholders with respect to material activities, value creation process, business highlights and future prospects. This Report follows and adopts guidelines as laid out by SEBI with respect to Annual Report.

#### Frameworks and guidelines

The content and structure of this Annual Report is guided by the framework endorsed by the Integrated Reporting <IR> Council. Besides, the Company fully complies with the NSE & BSE listings and SEBI Compliances. It is committed to embracing best practices in reporting to ensure transparency and better stakeholder engagement.

#### Scope and boundary

This Annual Report comprises all the relevant aspects of the operations of Metropolis. It also consists of the desired statutory disclosures and audited annual financial statements for the year ended March 31, 2023. All the subsidiaries are included in the consolidated financial information.

#### Assurance

Metropolis' Board of Directors and its subcommittees have reviewed the Report and satisfied themselves on the materiality, accuracy and balance of disclosures in this Report. The Board has not sought independent assurance of the Report, other than for the annual financial statements.

#### Feedback

The valuable feedback is integral to the continuous improvement of our reporting journey. Kindly direct your comments to secretarial@metropolisindia.com.

#### **Forward-looking statements**

This document contains statements about expected future events and financials of Metropolis Healthcare Limited ('Metropolis' or 'MHL' or 'Our Company'), which are forward-looking. By their nature, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is a significant risk that the assumptions, predictions and other forward-looking statements may not prove to be accurate. Readers are cautioned not to place undue reliance on forward-looking statements as several factors could cause assumptions, actual future results, and events to differ materially from those expressed in the forward-looking statements. Accordingly, this document is subject to the disclaimer and qualified in its entirety by the assumptions, qualifications and risk factors referred to in the Management Discussion and Analysis section of this Annual Report.

#### Investor Information

| BSE Code       | 542650             |
|----------------|--------------------|
| NSE Symbol     | METROPOLIS         |
| Bloomberg Code | METROHL:IN         |
| AGM Date       | August 17, 2023    |
| AGM Mode       | Video Conferencing |

For more investor-related information, please visit https://www.metropolisindia.com/investors

# or, simply scan to view the online version of the Report



# **Read Inside**

### **Corporate Overview**

| 02                | Embracing the Unpredictable. Achieving the Remarkable |
|-------------------|---|
| 04                | Key Highlights of FY 2022-23                          |
| 06                | Corporate Identity                                    |
| 10                | Milestones  |
| 12                | Chairman's Communique                                 |
| 16                | Letter From the Managing Director                     |
| 22                | Strategic Priorities                                  |
| 26                | Business Model  |
| 28                | Financial Capital                                     |
| 30                | Service Capital                                       |
| 32                | Intellectual Capital                                  |
| 38                | Materiality Assessment                                |
| 40                | Environment, Social and Governance at Metropolis      |
| 58                | Achieving Progress with Remarkable Leadership         |
| 59                | Embracing Remarkable Achievements                     |
| 62                | Corporate Information                                 |
|                   |   |
| Statutory Reports |   |
| 63                | Management Discussion and Analysis                    |
| 69                | Business Responsibility and Sustainability Report     |

- **112** Boards' Report
- 137 Corporate Governance Report

## **Financial Statements**

- 161 Standalone
- 240 Consolidated
- 315 Notice

# **Embracing the Unpredictable. Achieving the Remarkable.**

Healthcare has always been a dynamic field, one that constantly deals with new challenges and utmost chaos as the providers make every possible effort to save lives and ensure a healthy and happy life experience for people. However, the industry has undergone one of its most extensive transformations in the wake of the Covid-19 pandemic. Today, customer preferences have changed significantly, and the methods of healthcare delivery are being changed to address prevailing and future needs.

Embracing the Unpredictable says about our firm belief in looking at the silver lining in each cloud and finding ways to thrive amidst uncertainties. For us, healthcare delivery is not only about ensuring that the patient is cured of a disease or an injury, but also helping every individual attain a state of holistic wellness. It is this emphasis on quality and consistency of care that has enabled us to remain resilient and relevant to people and be among the frontrunners in the diagnostic services arena. Alongside human resilience and care, we have also been steadily enhancing the usage of cutting-edge technologies for diagnostic services that help our customers proactively take charge of their wellness. We have also enhanced our IT capabilities by introducing a B2C application to have a 360-degree view of customers for better life cycle management. Through this, we hope to realize our goal of providing customers with an omni channel experience of Metropolis, while also ensuring faster turnaround time and enhancing our Net Patient Score of Customer Loyalty and Satisfaction. We also have launched a renewed version of our Patient App along with a WhatsApp bot to provide convenient and accessible services to our patients. The latest version of the app has not only made it easier for them to access reports, book tests,

and find nearest centers but also provides them with several technology features such as tracking of samples, phlebotomists and so on. We have been taking our diagnostic services not only to the Tier 2 and Tier 3 cities, but also the micro markets. Towards this end, we have opened new laboratories in strategic locations to ensure wider access to our services and are constantly exploring new testing capabilities to meet the evolving needs of our patients and customers. The overarching vision at Metropolis is to overcome all challenges through technology and resilience and ensure that our business as well as the communities we serve, continue to thrive amidst chaos as well. We remain committed to sustainable growth and integrating sustainability principles across our value chain to create long-term value for all our stakeholders.

Apart from simplification of our customercentric processes, we are also heavily investing in building technology that ensures accuracy, while performing more complex tests faster. The aim is to also deliver timely and accurate diagnostic results that support patients in their healthcare decisions. In fact, it is this holistic emphasis on guality, science and innovation, speed and access that has enabled Metropolis to hold its ground and grow sustainably in the face of competition posed by large conglomerates, pharma players, and digital-first start-ups. We have significant leverage over these players who have been trying to capture the market on the virtue of low-priced solutions that often fail to achieve the quality and accuracy benchmarks of a player like Metropolis. It is this customercentricity that has kept us in a strong position to achieve the remarkable growth in future.



## KEY HIGHLIGHTS OF FY 2022-23

# **Embracing the Challenges. Delivering Remarkable Results.**

# **Healthy finances**

Rs. 1,148 Crs Total Revenue

**Rs. 143.4** Crs

**24.5** Mn Volume (Excl. Covid PCR and Covid Allied Tests) Rs. 293 Crs

**12.5%** PAT Margin

**21.2** Mn Core Business Volume (excl. Covid, Covid Allied, PPP & Hi-tech) 25.5% EBITDA Margin

Rs. 1,104 Crs Revenue Excl. Covid PCR & Covid Allied Tests

Rs. 949 Crs Core Business Revenue

# **Robust operations**

**12.2** Mn Number of Patient Visits

Rs. 453 Revenue per Test

**13** Regional Labs 25.3 Mn Number of Tests

175+ Advanced Clinical Laboratories

12,000 + Patient Touch Points Rs. 944 Revenue per Patient

**3,675** Patient Service Centres



## CORPORATE IDENTITY

# **Embracing the Unpredictable. Building a Legacy.**

LARGE TEST MENU

WIDE NETWORK TECHNOLOGY-ENABLED CUSTOMER SERVICE

AFFORDABLE TESTS ACCURATE TEST RESULTS

# This is Us...Metropolis and this is the story of our commitment to **Embrace** the Unpredictable Conditions and Achieve the Remarkable Growth

Metropolis Healthcare Limited ('Metropolis' or 'MHL' or 'Our Company') is one of the leading diagnostic chains in the healthcare sector, offering comprehensive and innovative best-in-class diagnostic services to its customers across India.



Our presence and suite of offerings Offering a comprehensive range of **4,000+** clinical laboratory tests and profiles

Aggressively focusing on advancing our technology to engage with our customers in a new way Helping customers access **complex** tests **accurately** and quickly

Focusing on the wellness segment by providing premium wellness packages for our core markets Improving and upgrading the overall quality standards

Significantly guiding our customers to find a cure and improve long-term health and well-being Onboarding specialist doctors to diagnose different tests

Deepening presence in Tier 2 and Tier 3 cities



## **Our key differentiators**

# A conclusive diagnosis

A large test menu backed by the highest standards of quality

#### **Customer-centric**

Diagnostic company with convenience and test accuracy at the core of service standards

#### Presence across India

A vast and unmatched service network

#### **Consistent operations**

Seamless blood collection, hygienic collection setup to timely report delivery every time



Having a presence across the value chain as we are a national player Providing high-valueadded specialized tests Reporting highquality earnings and profitability

## Achieving the remarkable: Quick facts

40+ Years of Credible Experience

4,000+ Tests and Profiles

~9,000 Mn Pick-up Points **1** st Global Reference Lab in Mumbai

20 States

754 Assisted Referral Centers (ARC) 27 NABL-Accredited Labs

**220** cities PAN India Presence

# Achieving the Remarkable with a Clear Purpose



To be a respected healthcare brand trusted by clinicians, patients and stakeholders. Positively impact the lives of patients in their most anxious times and turn their anxiety into assurance.



RARF

6

# Mission

Helping people stay healthy by accurately revealing their inner health.



INTEGRITY is in our VEINS

EMPATHY is in our BLOOD ACCURACY is in our DNA

## Our accredited certifications for achieving the remarkable

Mumbai lab is CAP accredited since 2005 All our facilities are NABL accredited More than 75% reports are generated by accredited labs NABL accreditation follows the ISO-15189 standard and is recognized by ILAC and APLAC

CAP: College of American Pathologists

NABL: National Accreditations Board for Testing and Calibration Laboratories